Formation development and evaluation of microsphere of sulfasalazine for the treatment inflammatory bowel diseases
Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disorder of the small intestine and colon. IBD includes ulcerative colitis (UC) and Crohn’s disease (CD), and it is a main reason for the expansion of colon cancer, referred to as colitis-associated cancer (CAC). Oral colon-targeted microsphere based drug delivery system containing sulfasalazine was prepared, optimized and characterized. The microspheres were effectively prepared by simple emulsification phase-separation technique followed by cross-linking. The formulations were optimized on the basis of drug: polymer ratio, stirring speed, concentration of glutaraldehyde. The prepared microspheres were characterized on the basis of morphology, entrapment efficiency, particle size and in-vitro release.
Keywords: Microspheres, Sulfasalazine, Inflammatory bowel disease, Colon-targeted, Chitosan
Keywords:
Microspheres, Sulfasalazine, Inflammatory bowel disease, Colon-targeted, ChitosanDOI
https://doi.org/10.22270/jddt.v11i5-S.5120References
1. Kumar KPS, Bhowmik D, Srivastava S, Paswan S, Dutta AS. Sustained release drug delivery system potential. The Pharma Innovation 2012; 1(2):48-60.
2. Dehghan S, Aboofazeli R, Avadi M, Khaksar R. Formulation optimization of nifedipine containing microspheres using factorial design, African J Pharm Pharmacol 2010; 4(6):346-354.
3. Lohani A, Gangwar PC. Mucoadhesive microspheres: A novel approach to increase gastroretention. ChronicYoung Scient.2012; 3(2):121-128. https://doi.org/10.4103/2229-5186.98684
4. Alagusundaram M, Madhusudana CC, Umasharkari K, Badrinath AV, Lavanya C, Ramkanth S. Microspheres as a novel drug delivery system, Int J ChemTech Res 2009;1(3):526-534.
5. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12: S3-S9. https://doi.org/10.1097/01.MIB.0000195385.19268.68
6. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474:307-317. https://doi.org/10.1038/nature10209
7. Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol Mech 2016; 11:127-148. https://doi.org/10.1146/annurev-pathol-012615-044152
8. Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy 2010; 1(1):79-85. https://doi.org/10.4103/0975-8453.59516
9. Leuva VR, Patel BG, Chaudhary DJ, Patel JN, Modasiya MMK. Oral colon-specific drug delivery system. J Pharm Res 2012; 5(4):2293-7.
10. Kumar M, Ali A, Kaldhone P, Shirode A, Kadam VJ. Report on pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Res 2010; 3(3):157-159.
11. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 2010; 25(2):79-87. https://doi.org/10.5001/omj.2010.24
12. Zheng W, Winter SM, Mayersohn M, Bishop JB, Sipes IG. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and itsmetabolites in B6C3F1 mice. Drug Metab Dispos 1993; 21(6):1091-1097.
13. Ramezani Z, Dibaee N. Determination of sulfasalazine in sulfasalazine tablets using silver nanoparticles. Iranian J of Pharm Sci 2012; 8(2):129-134.
14. Jain SK, Jain NK, Gupta Y, Jain A, Jain D, Chaurasia M. Mucoadhesive chitosan microspheres for non-invasive and improved nasal delivery of insulin, Indian J Pharm Sci 2007; 69 (4):498-504. https://doi.org/10.4103/0250-474X.36933
2. Dehghan S, Aboofazeli R, Avadi M, Khaksar R. Formulation optimization of nifedipine containing microspheres using factorial design, African J Pharm Pharmacol 2010; 4(6):346-354.
3. Lohani A, Gangwar PC. Mucoadhesive microspheres: A novel approach to increase gastroretention. ChronicYoung Scient.2012; 3(2):121-128. https://doi.org/10.4103/2229-5186.98684
4. Alagusundaram M, Madhusudana CC, Umasharkari K, Badrinath AV, Lavanya C, Ramkanth S. Microspheres as a novel drug delivery system, Int J ChemTech Res 2009;1(3):526-534.
5. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12: S3-S9. https://doi.org/10.1097/01.MIB.0000195385.19268.68
6. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474:307-317. https://doi.org/10.1038/nature10209
7. Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol Mech 2016; 11:127-148. https://doi.org/10.1146/annurev-pathol-012615-044152
8. Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy 2010; 1(1):79-85. https://doi.org/10.4103/0975-8453.59516
9. Leuva VR, Patel BG, Chaudhary DJ, Patel JN, Modasiya MMK. Oral colon-specific drug delivery system. J Pharm Res 2012; 5(4):2293-7.
10. Kumar M, Ali A, Kaldhone P, Shirode A, Kadam VJ. Report on pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Res 2010; 3(3):157-159.
11. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 2010; 25(2):79-87. https://doi.org/10.5001/omj.2010.24
12. Zheng W, Winter SM, Mayersohn M, Bishop JB, Sipes IG. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and itsmetabolites in B6C3F1 mice. Drug Metab Dispos 1993; 21(6):1091-1097.
13. Ramezani Z, Dibaee N. Determination of sulfasalazine in sulfasalazine tablets using silver nanoparticles. Iranian J of Pharm Sci 2012; 8(2):129-134.
14. Jain SK, Jain NK, Gupta Y, Jain A, Jain D, Chaurasia M. Mucoadhesive chitosan microspheres for non-invasive and improved nasal delivery of insulin, Indian J Pharm Sci 2007; 69 (4):498-504. https://doi.org/10.4103/0250-474X.36933
Published
2021-12-06
Statistics
Abstract Display: 831 
PDF Downloads: 699 PDF Downloads: 138 How to Cite
1.
Tiwari T, Jain V, Jain SK, Khangar PK. Formation development and evaluation of microsphere of sulfasalazine for the treatment inflammatory bowel diseases. J. Drug Delivery Ther. [Internet]. 2021 Dec. 6 [cited 2026 Jan. 21];11(5-S):124-7. Available from: https://jddtonline.info/index.php/jddt/article/view/5120
Issue
Section
Research
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
1.
Tiwari T, Jain V, Jain SK, Khangar PK. Formation development and evaluation of microsphere of sulfasalazine for the treatment inflammatory bowel diseases. J. Drug Delivery Ther. [Internet]. 2021 Dec. 6 [cited 2026 Jan. 21];11(5-S):124-7. Available from: https://jddtonline.info/index.php/jddt/article/view/5120
.